Charles River Laboratories International Inc
NYSE:CRL

Watchlist Manager
Charles River Laboratories International Inc Logo
Charles River Laboratories International Inc
NYSE:CRL
Watchlist
Price: 196.22 USD 1.22%
Market Cap: 9.7B USD

Net Margin
Charles River Laboratories International Inc

-2.1%
Current
7%
Average
1%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2.1%
=
Net Income
-83.5m
/
Revenue
4B

Net Margin Across Competitors

No Stocks Found

Charles River Laboratories International Inc
Glance View

Nestled within the intricate maze of the global life sciences sector, Charles River Laboratories International Inc. stands as a pivotal player. With a legacy dating back to 1947, the company has carved out a niche in providing essential research models and preclinical services that underpin crucial drug development processes. Its journey began by breeding laboratory animals, an unassuming yet vital task that feeds the robust pipeline of scientific inquiry and pharmaceutical innovation. This foundational service, involving the provision of research models such as rats and mice, forms the bedrock upon which the company built its expansive portfolio. It primes the pumps of early-stage research for pharmaceutical and biotechnology firms, offering a reliable source of high-quality, disease-specific models that are indispensable for preclinical trials. Today, Charles River Laboratories has evolved into a comprehensive partner for the biomedical and pharmaceutical industries. It derives its revenue by encompassing a broad portfolio of offerings beyond animal models, venturing into the vast domain of comprehensive drug discovery and safety testing for new pharmaceuticals. This makes the company instrumental in speeding up the development pipeline—from concept to the cusp of clinical trials. By providing everything from lab services, safety assessments, and manufacturing support, Charles River facilitates the journey of a drug from an embryonic idea to a tangible, market-ready solution, all while ensuring compliance with strict regulatory standards. This integration across verticals not only enriches its value proposition but ensures a steady stream of revenue across various stages of the drug development lifecycle.

CRL Intrinsic Value
225 USD
Undervaluation 13%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2.1%
=
Net Income
-83.5m
/
Revenue
4B
What is the Net Margin of Charles River Laboratories International Inc?

Based on Charles River Laboratories International Inc's most recent financial statements, the company has Net Margin of -2.1%.

Back to Top